Study Finds Simple Change Can Help Manage Blood Sugar
People often experience glucose spikes after eating, particularly when consuming foods high in carbohydrates such as bread, pasta, rice and grains. It's become a known health hack that going on a post-meal walk can help curb sugary spikes caused by such foods.
But a study published on Scientific Reports on Wednesday took things even further. The researchers looked into the intricacies of the post-meal walk, particularly with how immediate one has to start walking to receive the most health benefits.
The study analyzed a group of 12 people to compare the difference between going on a 10-minute walk right after glucose intake and going on a 30-minute walk a half hour after glucose intake.
The findings showed that both methods significantly reduced average blood glucose levels compared to remaining at rest after a meal.
However, the 10-minute walk was deemed to be "uniquely effective" at minimizing the peak glucose levels for each individual compared to the delayed 30-minute walk.
Participants also rated the 10-minute walk as "significantly easier" than the longer one despite having to start the former with a fuller stomach.
It doesn't take a scientist to figure out that last part.
Getting a walk in earlier can yield even better results in terms of blood sugar maintenance than putting off a stroll just a little longer. The study suggests that not even tripling the walk duration would give you the same level of benefit.
That's a textbook example of when working smart simply beats working hard.Study Finds Simple Change Can Help Manage Blood Sugar first appeared on Men's Journal on Jul 5, 2025
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
14 minutes ago
- Medscape
Refine Your Application as Residency Deadline Approaches
The deadline for applying to residency programs is approaching, and as you prepare to apply to your chosen programs, here are some strategies to streamline the process while you get your plans and materials in order. Ensure Your Residency Portfolio Is Ready Consider these tips to keep you on track and organized. Start early and get organized. Whether your specialty uses Electronic Residency Application Service (ERAS) or another application platform, timelines with all key dates for the season are out. Keep this information handy and set alerts so you stay on track, recommended Meredith C. Thompson, MD, MAEd, associate professor and interim vice chair of Education, and interim assistant dean of student affairs, Department of Emergency Medicine, College of Medicine, University of Florida Health/Shands Hospital in Gainesville, Florida. The ERAS system begins accepting applications on September 3. Do your research. 'Formulate a system to compare and keep track of all the programs you're interested in. This includes any program characteristics that are important to you and your perceived competitiveness for the program. Your advisor can help with that, as can reputable data sources like Texas Star, AAMC [Association of American Medical Colleges] residency explorer or other specialty organization advising resources,' Thompson said. Another tip: Many programs also maintain social media presence and host virtual meet and greets on these platforms for applicants. Concentrate on recommendations. Ask for letters of recommendation at least 1 month in advance. 'Your goal is to have all application elements submitted by the time the platform opens to programs for viewing,' advised Thompson. Ensuring all items are received on time is key to maximizing your chances of obtaining interviews, she said. Meredith C. Thompson, MD, MAEd Assemble your team. Applying to residency is not a solo endeavor, so Thompson explained it's in your best interest to build a team to support you during the process. 'Key persons to have in your corner include a specialty specific advisor, editor, and interview preparer,' she said. Check your medical school's resources as many institutions provide students with access to a specialty specific advisor that can provide evidenced based advice personalized to your unique situation during the application process. If this is not available, Thompson recommended connecting to your student affairs dean who typically can help you with this information or guide you to appropriate data sources to help make these decisions. Lean on a support team. Complete one or more practice interviews with someone familiar with the interview format for your chosen specialty to become more comfortable, she suggested. 'Your support team is key in ensuring you are putting your best foot forward during the application and interview process,' Thompson said. Proofread your materials. Make sure all sections are completed and that your information is free from typos, said Mitchell Goldman, MD, senior associate dean for graduate medical education, professor of medicine, and designated institutional official at the University of Missouri School of Medicine in Columbia, Missouri. 'You want to impress anyone who reads your application and leave an impression of professionalism,' Goldman stated. 'Recommend having an experienced educator review your personal statement before submission to identify opportunities for improvement.' Be honest and genuine in your application. Goldman said to list hobbies, interests, and volunteer experiences that you could discuss in detail if asked about them during an interview. Be realistic in the scope. If you are applying to highly competitive specialties, consider a back-up plan and apply to acceptable programs or specialties, Goldman said. 'You want to be realistic about the programs you apply to and have a good chance for getting an interview at a number of programs,' he said. Be proactive. Reach out early and often for guidance from trusted sources. They may have prudent advice to share. In addition, be sure to follow-up. If your dream program hasn't extended an interview, consider sending an email to the program director and coordinator. 'Send only one (follow-up) email to communicate genuine interest,' Thompson said. 'Application season is not the time to take a wait and see approach.' How do you use your medical school's resources to help with the process? Your medical school's student affairs office is a wealth of information for your residency-application process. They can provide guidance on evidence-based resources to inform your decision making. Also, your medical school may have a career advising program that can identify local specialty specific advisors to give personalized guidance. 'In addition to this, they can be a resource to review personal statements, provide mock practice interviews, and assess your total application for your competitiveness for different programs,' Thompson said. Finally, medical school alumni programs can also be a resource for these types of services. What do these experts say about the rewards of residency? Residency allows you to focus on your unique interests and talents. 'This is rewarding as it allows you to enhance your clinical skills to more meaningfully contribute to patient care in a particular niche as well as develop professionally under the guidance of experts and a network of physicians with similar career goals,' said Thompson. 'Moreover, you gain a cadre of coresidents that share the journey with you that you can learn from and lean on for support.' Your residency is also a time where you can be immersed in your area of interest, be educated by those with extensive expertise and teaching skills and a time of rapid growth in your personal and professional life, said Goldman. 'Residency experiences are some of the most rewarding experiences of a physician's life,' he said. 'It is also a time to have fun being with individuals with shared interest. You can make life-long friends, learn about yourself and what you value most moving forward.'
Yahoo
22 minutes ago
- Yahoo
Shelby Lambdin appointed to four-month stint on Spokane City Council
Jul. 28—Shelby Lambdin was appointed to a four-month stint on the Spokane City Council Monday, filling a seat representing south Spokane vacated by former Councilwoman Lili Navarrete, who was herself appointed to the seat in early 2024 and resigned effective July 1 citing health concerns. Lambdin is the population health director at the Community Health Association of Spokane, more commonly known as CHAS Health. She was appointed with a 4-2 vote; Councilmen Jonathan Bingle and Michael Cathcart opposed her appointment. Though voters will have an opportunity in November to choose a successor for a full four-year term — Kate Telis and Alejandro Barrientos are currently vying for the seat — the City Council is responsible for appointing a temporary replacement when a seat is vacated early. Bingle and Cathcart had advocated to appoint Ryan Oelrich, who served on the City Council during a roughly two-month stint in 2023, arguing that the experience would make it easier for Oelrich to hit the ground running as the council prepares to balance the city's budget in the coming months. Ahead of the vote, Councilman Paul Dillon thanked the applicants for the position but said he and Council President Betsy Wilkerson had wanted to bring on a new voice to the council. Lambdin has no political, elected or government experience. During her public interview, Lambdin argued her experience in public health would bring expertise to the council on addressing relevant issues. She advocated for reducing the city's costs by using technology and artificial intelligence to replace personnel and streamline operations. Lambdin also argued in favor of programs to make the city's outdoor recreation more accessible to marginalized communities and for advancing the council's work on making various services available in other languages. Solve the daily Crossword
Yahoo
43 minutes ago
- Yahoo
ViroCell Biologics and AvenCell Therapeutics Announce Retroviral Vector Manufacturing Collaboration to Accelerate Development of Novel Allogeneic CAR-T Therapies for Blood Cancers
AvenCell selected ViroCell for retroviral vector CDMO services to drive its pipeline of innovative allogeneic CAR T-cell therapies, based on ViroCell's deep expertise and track record. LONDON & NEW YORK, July 29, 2025--(BUSINESS WIRE)--ViroCell Biologics ("ViroCell"), a specialist viral vector Contract Development and Manufacturing Organisation ("CDMO") for cell and gene therapy (CGT) clinical trials, announces a manufacturing collaboration with and the successful delivery of a novel retroviral vector to AvenCell Therapeutics, Inc. ("AvenCell"), a leading clinical-stage cell therapy company focused on advancing allogeneic switchable CAR-T cell therapies. This first retroviral vector will be used to manufacture AVC-203, an investigational CD19/CD20 dual-targeted cell therapy for the treatment of B cell malignancies and autoimmune diseases. AvenCell's AV203 is its second investigational cell therapy using its differentiated allogeneic engineering to provide an "off-the-shelf" product engineered to overcome graft-versus-host disease as well as graft rejection by host T and Natural Killer ("NK") cells. AVC-203 is designed to achieve superior efficacy compared to currently-approved CAR-Ts while enabling immediate treatment and greater patient access at much lower cost and complexity. The further inclusion of AvenCell's RevCAR™ receptor in AVC203 allows for additional antigen targeting (with "off/on" capability in vivo) beyond CD19 and CD20. AvenCell selected ViroCell as its partner to manufacture the retroviral vector for this program based on the CDMO's expertise and track record in delivering high yield vectors at speed. Incorporating a cell line acquired by AvenCell into the GMP manufacturing process, ViroCell successfully delivered a high yield vector while meeting AvenCell's accelerated timeline. This program evidences ViroCell's ability to deliver a bespoke, complex manufacturing process in the allogeneic CAR-T cell therapy space, ultimately, enabling AvenCell's timelines for clinical entry. AvenCell's AVC-203 is expected to enter a first-in-human phase I study in patients with relapsed/refractory B cell lymphoma in H2/2025. John W. Hadden II, CEO of ViroCell, commented: "We are thrilled to partner with AvenCell and support their innovative allogeneic CAR-T therapy platform. I am proud of Team ViroCell's accomplishments on the successful end-to-end delivery of this retroviral vector and accelerating a novel therapy into clinical development in an area of high unmet need. We look forward to continuing our work with AvenCell on their exciting platform." Andrew Schiermeier, Ph.D., CEO, AvenCell, added: "We are delighted with ViroCell's performance in process development and GMP manufacture of this complex retroviral vector. We selected ViroCell to support our platform because we knew that they could execute reliably in areas where other CDMOs can't. The delivery of this retroviral vector for AVC-203 is proof that our trust in ViroCell was well placed." Notes to editor: ViroCell ViroCell Biologics is an innovation-driven Contract Development and Manufacturing Organization ("CDMO") focused exclusively on the design, de-risking, and GMP manufacture of viral vectors for clinical trials. Built around one of the most prolific academic viral vector manufacturing teams, ViroCell was created to address the global demand for precisely engineered viral vectors. The team leverages its deep track record to help clients to de-risk and accelerate novel cell and gene therapies into and through clinical development, with a mission of being the partner of choice for corporate and academic innovators. Focused initially on manufacturing lentiviral and retroviral vectors, ViroCell enables clients to start clinical trials on a scalable platform, delivering value by reducing costs, time and regulatory risk. AvenCell Therapeutics AvenCell derives its name from the French word "avenir" to reflect the aim to be the FUTURE of cell therapy. AvenCell is building a truly transformative cell therapy company that targets difficult-to-treat cancers, with its lead programs focusing on acute myeloid leukemia (AML) and additional programs targeting other hematological malignancies. AvenCell was formed with the goal to create truly allogeneic cells that persist as long or longer than autologous therapies and develop a universal and switchable construct that allows complete control and target redirection of T cells after they are infused into a patient. Integration of these two platforms allows for complete separation of the manufacturing of cells from ultimate patient and cancer target, thus providing significant scalability potential at orders of magnitude more efficient than current approaches. AvenCell Therapeutics, Inc. was launched in 2021 by Blackstone Life Sciences, Cellex Cell Professionals, and Intellia Therapeutics. AvenCell is headquartered in Watertown, Massachusetts with additional R&D and manufacturing operations in Dresden, Germany. View source version on Contacts For more information, please contact: ViroCell John W. Hadden II, CEOinfo@ For media enquiries, please contact: ViroCell – FTI Consulting Simon Conway / Tim StamperViroCell@ +44 (0)20 3727 1000 AvenCell – H Advisors Emma +1 (917) 763-6685 擷取數據時發生錯誤 登入存取你的投資組合 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤 擷取數據時發生錯誤
